GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-8047-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$41.14 billion
Profitability
Miscellaneous
Employees95,490
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable
GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions
What is GlaxoSmithKline's stock symbol?
GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?
GlaxoSmithKline announced a quarterly dividend on Friday, May 3rd. Investors of record on Friday, May 17th will be given a dividend of $0.4953 per share on Thursday, July 11th. This represents a $1.98 dividend on an annualized basis and a yield of 4.14%. The ex-dividend date of this dividend is Thursday, May 16th. View GlaxoSmithKline's Dividend History.
How were GlaxoSmithKline's earnings last quarter?
GlaxoSmithKline plc (NYSE:GSK) posted its quarterly earnings results on Wednesday, October, 30th. The pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.10. The pharmaceutical company earned $11.57 billion during the quarter, compared to analyst estimates of $11.34 billion. GlaxoSmithKline had a net margin of 13.76% and a return on equity of 92.73%. View GlaxoSmithKline's Earnings History.
When is GlaxoSmithKline's next earnings date?
What price target have analysts set for GSK?
12 analysts have issued 1-year price objectives for GlaxoSmithKline's stock. Their forecasts range from $45.00 to $53.00. On average, they anticipate GlaxoSmithKline's stock price to reach $49.00 in the next twelve months. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.
What is the consensus analysts' recommendation for GlaxoSmithKline?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 2 sell ratings, 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.
Has GlaxoSmithKline been receiving favorable news coverage?
News coverage about GSK stock has been trending very positive this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlaxoSmithKline earned a media sentiment score of 3.4 on InfoTrie's scale. They also assigned media coverage about the pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for GlaxoSmithKline.
Are investors shorting GlaxoSmithKline?
GlaxoSmithKline saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 7,110,000 shares, an increase of 6.0% from the November 28th total of 6,710,000 shares. Based on an average daily volume of 2,680,000 shares, the short-interest ratio is presently 2.7 days. Currently, 0.3% of the company's shares are short sold. View GlaxoSmithKline's Current Options Chain.
Who are some of GlaxoSmithKline's key competitors?
Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).
What other stocks do shareholders of GlaxoSmithKline own?
Who are GlaxoSmithKline's key executives?
GlaxoSmithKline's management team includes the folowing people:
- Ms. Emma N. Walmsley, CEO & Director (Age 49)
- Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
- Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
- Mr. Jack Bailey, Pres of US Pharmaceuticals
- Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)
Who are GlaxoSmithKline's major shareholders?
GlaxoSmithKline's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Chemung Canal Trust Co. (0.01%), Hennessy Advisors Inc. (0.00%), Farmers Trust Co. (0.00%), Ipswich Investment Management Co. Inc. (0.00%), AE Wealth Management LLC (0.00%) and Hamilton Wealth LLC (0.00%). View Institutional Ownership Trends for GlaxoSmithKline.
Which major investors are selling GlaxoSmithKline stock?
GSK stock was sold by a variety of institutional investors in the last quarter, including Farmers Trust Co., Zeke Capital Advisors LLC, Hennessy Advisors Inc., Fluent Financial LLC, Mountain Capital Investment Advisors Inc, Chemung Canal Trust Co., Allred Capital Management LLC and Livingston Group Asset Management CO operating as Southport Capital Management. View Insider Buying and Selling for GlaxoSmithKline.
Which major investors are buying GlaxoSmithKline stock?
GSK stock was acquired by a variety of institutional investors in the last quarter, including Boenning & Scattergood Inc., AE Wealth Management LLC, Curbstone Financial Management Corp, OLD National Bancorp IN, Ingalls & Snyder LLC, First Hawaiian Bank, Accurate Investment Solutions Inc. and Rockland Trust Co.. View Insider Buying and Selling for GlaxoSmithKline.
How do I buy shares of GlaxoSmithKline?
Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is GlaxoSmithKline's stock price today?
One share of GSK stock can currently be purchased for approximately $47.89.
How big of a company is GlaxoSmithKline?
GlaxoSmithKline has a market capitalization of $119.45 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 95,490 workers across the globe.View Additional Information About GlaxoSmithKline.
What is GlaxoSmithKline's official website?
How can I contact GlaxoSmithKline?
GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]
MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
